2023 World Conference on Lung Cancer (Posters)-EP12.01. Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

EP12.01. Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This presentation provides the final report on the real-world effectiveness of sequential treatment with afatinib and osimertinib in patients with advanced non-small cell lung cancer (NSCLC) who have the EGFR mutation. The study aimed to evaluate the time-on-treatment (TOT) and overall survival (OS) outcomes of patients who received this sequential therapy compared to other second-line regimens.<br /><br />The study reviewed the medical records of 401 patients who received first-line treatment with afatinib. Of these patients, 166 had the T790M mutation and received second-line treatment with osimertinib, while 235 patients had unproven T790M and received other second-line agents. The median TOT on afatinib was 15.0 months, and on osimertinib, it was 11.9 months. The median OS in the osimertinib group was 54.3 months, longer than the comparator group.<br /><br />The study found that patients who received osimertinib had the longest OS when they had the Del19 mutation. This real-world study reports positive results of sequential afatinib and osimertinib therapy in Asian patients with EGFR NSCLC who acquired the T790M mutation, especially those with the Del19 mutation.<br /><br />This study is one of the largest real-world studies to date, providing encouraging evidence of the effectiveness of sequential afatinib and osimertinib therapy in treating EGFR-positive advanced NSCLC. The findings suggest that this treatment approach may be beneficial for patients with the T790M mutation, particularly those with the Del19 mutation.

Asset Subtitle

Tae Won Jang

Meta Tag

Speaker Tae Won Jang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

osimertinib

non-small cell lung cancer

EGFR mutation

time-on-treatment

overall survival

T790M mutation

second-line treatment

Del19 mutation

real-world study